What is Elastrin Therapeutics?
Based in South Carolina, Elastrin Therapeutics is a pioneering biotechnology firm dedicated to the development of novel therapies designed to reverse cardiovascular disease. The company's core technology, rooted in over 20 years of research by Dr. Naren Vyavahare at Clemson University, centers on a proprietary platform that restores degraded elastin. By effectively removing harmful calcification that contributes to arterial stiffness, the company's platform enhances drug efficacy while simultaneously mitigating systemic side effects through precise particle design and targeted delivery mechanisms. This dual-action approach represents a significant shift in how clinicians may eventually treat age-related vascular degradation.
How much funding has Elastrin Therapeutics raised?
Elastrin Therapeutics has raised a total of $12.5M across 2 funding rounds:
Angel/Seed
$2.5M
Unspecified
$10M
Angel/Seed (2021): $2.5M with participation from Kizoo
Unspecified (2022): $10M led by Kizoo
Key Investors in Elastrin Therapeutics
Kizoo
Kizoo is an investment firm focused on groundbreaking technologies in the fields of rejuvenation biotech and Internet & SaaS. The company aims to extend healthy lifespans through innovative therapies that address the aging process and its related diseases.
What's next for Elastrin Therapeutics?
With the recent infusion of capital, Elastrin Therapeutics is poised to transition its research into more advanced clinical phases. The strategic focus will likely involve scaling the manufacturing of its targeted particles and expanding its pipeline of therapeutic candidates. As the company moves forward, the primary objective will be to demonstrate the safety and efficacy of its elastin-restoration technology in human trials, a critical milestone for any biotech firm operating in the cardiovascular space. Investors are closely watching how this platform will integrate into existing treatment protocols for chronic vascular conditions, potentially setting a new standard for regenerative medicine in the aging population.
See full Elastrin Therapeutics company page
